tirzepatide trial obesity without diabetes Frontiers Read now: The SURPASS-EARLY trial
Description
Others see gradual, steady progress that accelerates around weeks 8 to 12
The study was published in 2025, but reported data from 2022-2023
Insulin lowers blood sugar
Important safety considerations include a contraindication in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
When used as monotherapy or with medications that do not independently cause hypoglycemia, tirzepatide has a low intrinsic risk of causing clinically significant hypoglycemia
Step 3: Clean the vial stopper
